Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes

References

• Derfuss T, Mehling M, Papadopoulou A, et al., Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19(4):336–347. .
   PubMed Web of Science ®Google Scholar
• Ben-Hur T. Cell therapy for multiple sclerosis. Neurotherapeutics. 2011;8:625–642.
   PubMed Web of Science ®Google Scholar
• Sedal L, Winkel A, Laing J, et al. Current concepts in multiple sclerosis therapy. Degener Neurol Neuromuscul Dis. 2017;7:109–125.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. The American Journal of Medicine. 2020;133(12):1380–1390.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski AJ, Stewart JM, Cho JJ, et al. Nano and microparticle emerging strategies for treatment of autoimmune diseases: multiple sclerosis and type 1 diabetes. Adv Healthc Mater. 2020;9(11):e2000164.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh Bejargafshe M, Hedayati M, Zahabiasli S, et al. Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis. Stem Cell Investig. 2019;6:44.
   PubMedGoogle Scholar
• Karussis D, Kassis I. Use of stem cells for the treatment of multiple sclerosis. Expert Rev Neurother. 2007;7(9):1189–1201.
   PubMedGoogle Scholar
• Darlington PJ, Boivin MN, Bar-Or A. Harnessing the therapeutic potential of mesenchymal stem cells in multiple sclerosis. Expert Rev Neurother. 2011;11(9):1295–1303.
   PubMed Web of Science ®Google Scholar
• Lycke J, Lenhoff S. Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis. Ther Adv Neurol Disord. 2020;13:1756286420929467.
   Web of Science ®Google Scholar
• Aoi T. 10th anniversary of iPS cells: the challenges that lie ahead. J Biochem. 2016;160(3):121–129.
   PubMed Web of Science ®Google Scholar
• Samjoo IA, Worthington E, Drudge C, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255–1274.
   PubMed Web of Science ®Google Scholar
• Moghadam S, Erfanmanesh M, Esmaeilzadeh A. Interleukin 35 and hepatocyte growth factor; as a novel combined immune gene therapy for multiple sclerosis disease. Med Hypotheses. 2017;109:102–105.
   PubMed Web of Science ®Google Scholar
• Maguire CA, Ramirez SH, Merkel SF, et al. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics. 2014;11:817–839.
   PubMed Web of Science ®Google Scholar
• Sudhakar V, Richardson RM. Gene therapy for neurodegenerative diseases. Neurotherapeutics. 2019;16(1):166–175.
   PubMed Web of Science ®Google Scholar
• Tang R, Xu Z. Gene therapy: a double-edged sword with great powers. Mol Cell Biochem. 2020;474(1–2):73–81.
   PubMed Web of Science ®Google Scholar
• Rueda F, Cruz LJ. Targeting the brain with nanomedicine. Curr Pharm Des. 2017;23(13):1879–1896.
   PubMed Web of Science ®Google Scholar
• Hanif S, Muhammad P, Chesworth R, et al. Nanomedicine-based immunotherapy for central nervous system disorders. Acta Pharmacol Sin. 2020;41(7):936–953.
   PubMed Web of Science ®Google Scholar
• Engel E, Michiardi A, Navarro M, et al. Nanotechnology in regenerative medicine: the materials side. Trends Biotechnol. 2008;26(1):39–47.
   PubMed Web of Science ®Google Scholar
• Prabhakaran MP, Venugopal JR, Ramakrishna S. Mesenchymal stem cell differentiation to neuronal cells on electrospun nanofibrous substrates for nerve tissue engineering. Biomaterials. 2009;30(28):4996–5003.
   PubMed Web of Science ®Google Scholar
• Akhavan D, Alizadeh D, Wang D, et al. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019;290(1):60–84.
   PubMed Web of Science ®Google Scholar
• Chen Y, Sun J, Liu H, et al. Immunotherapy deriving from CAR-T cell treatment in autoimmune diseases. J Immunol Res. 2019;2019:5727516.
   PubMed Web of Science ®Google Scholar
• Critical Appraisal Skills Programme. CASP checklists. 2018 27th January 2020. Available from: https://casp-uk.net/casp-tools-checklists/.
   Google Scholar
• Fernández O, Izquierdo G, Fernández V, et al., Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: a triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLoS One. 2018;13(5):e0195891. .
   PubMed Web of Science ®Google Scholar
• Ruiz-Argüelles GJ, León-Peña AA, León-González M, et al., A feasibility study of the full outpatient conduction of hematopoietic transplants in persons with multiple sclerosis employing autologous non-cryopreserved peripheral blood stem cells. Acta Haematol. 2017;137(4):214–219. .
   PubMed Web of Science ®Google Scholar
• Llufriu S, Sepúlveda M, Blanco Y, et al., Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS One. 2014;9(12):e113936. .
   PubMed Web of Science ®Google Scholar
• Duma C, Kopyov O, Kopyov A, et al., Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: results of a 3-year phase 1 study of 113 injections in 31 patients. Mol Biol Rep. 2019;46(5):5257–5272. .
   PubMed Web of Science ®Google Scholar
• Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al., Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67(10):1187–1194. .
   PubMed Web of Science ®Google Scholar
• Espigado I, Marín-Niebla A, Rovira M, et al., Phase I/II trials of autologous peripheral blood stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the Spanish experience. Transplant Proc. 2003;35(2):742–743. .
   PubMed Web of Science ®Google Scholar
• Moore JJ, Massey JC, Ford CD, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(5):514–521.
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981–988.
   PubMed Web of Science ®Google Scholar
• Lublin FD, Bowen JD, Huddlestone J, et al. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Mult Scler Relat Disord. 2014;3(6):696–704.
   PubMed Web of Science ®Google Scholar
• Li JF, Zhang DJ, Geng T, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplant. 2014;23(1_suppl):113–122.
   Web of Science ®Google Scholar
• Shevchenko JL, Kuznetsov AN, Ionova TI, et al., Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012;40(11):892–898. .
   PubMed Web of Science ®Google Scholar
• Bonab MM, Sahraian MA, Aghsaie A, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study. Curr Stem Cell Res Ther. 2012;7(6):407–414.
   PubMed Web of Science ®Google Scholar
• Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant. 2012;47(7):946–951.
   PubMed Web of Science ®Google Scholar
• Xu J, Ji BX, Su L, et al., Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Ann Hematol. 2011;90(3):343–348. .
   PubMed Web of Science ®Google Scholar
• Rice CM, Mallam EA, Whone AL, et al. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther. 2009;87(6):679–685.
   Web of Science ®Google Scholar
• Capello E, Saccardi R, Murialdo A, et al. Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurol Sci. 2005;26(S4):200–203.
   Web of Science ®Google Scholar
• Healey KM, Pavletic SZ, Al-Omaishi J, et al. Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation. Mult Scler. 2004;10(3):284–289.
   PubMed Web of Science ®Google Scholar
• Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7):2364–2372.
   PubMed Web of Science ®Google Scholar
• Carreras E, Saiz A, Marín P, et al. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica. 2003;88(3):306–314.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Burman J, et al., Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2):165–174. .
   PubMed Web of Science ®Google Scholar
• Shevchenko YL, Novik AA, Kuznetsov AN, et al., High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol. 2008;36(8):922–928. .
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK, et al., High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Neurology. 2017;88(9):842–852. .
   PubMed Web of Science ®Google Scholar
• Atkins HL, Bowman M, Allan D, et al., Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388(10044):576–585. .
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol. 2015;72(2):159–169.
   PubMed Web of Science ®Google Scholar
• Berard JA, Bowman M, Atkins HL, et al. Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. J Neurol Sci. 2014;336(1–2):132–137.
   PubMed Web of Science ®Google Scholar
• Pender MP, Csurhes PA, Smith C, et al. Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis. JCI Insight. 2018;3(22):e124714.
   PubMed Web of Science ®Google Scholar
• Riordan NH, Morales I, Fernández G, et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018;16(1):1–12.
   PubMed Web of Science ®Google Scholar
• Harris VK, Stark J, Vyshkina T, et al. Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis. EBioMedicine. 2018;29:23–30.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Imrey PB, Planchon SM, et al. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Mult Scler. 2018;24(4):501–511.
   PubMed Web of Science ®Google Scholar
• Dahbour S, Jamali F, Alhattab D, et al. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: clinical, ophthalmological and radiological assessments of safety and efficacy. CNS Neurosci Ther. 2017;23(11):866–874.
   PubMed Web of Science ®Google Scholar
• Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11(2):150–156.
   PubMed Web of Science ®Google Scholar
• Connick P, Kolappan M, Patani R, et al. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. 2011;12(1):62.
   PubMed Web of Science ®Google Scholar
• Yamout B, Hourani R, Salti H, et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. J Neuroimmunol. 2010;227(1–2):185–189.
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Cohen B, et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009;8(3):244–253.
   PubMed Web of Science ®Google Scholar
• Su L, Xu J, Ji BX, et al. Autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Int J Hematol. 2006;84(3):276–281.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805–816.
   PubMed Web of Science ®Google Scholar
• Sun W, Popat U, Hutton G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(5):996–1008.
   PubMed Web of Science ®Google Scholar
• Burt RK, Cohen BA, Russell E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003;102(7):2373–2378.
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Saccardi R, Filippi M, et al. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology. 2001;57(1):62–68.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Dobrescu A, Evans TS, et al. The predictive validity of quality of evidence grades for the stability of effect estimates was low: a meta-epidemiological study. J Clin Epidemiol. 2016;70:52–60.
   PubMed Web of Science ®Google Scholar
• American Academy of Neurology. Clinical practice guideline process manual. 2017. ed Paul S. MN: American Academy of Neurology 12th Fepruary 2020. Available from: https://www.aan.com/siteassets/home-page/policy-and-guidelines/guidelines/about-guidelines/17guidelineprocman_pg.pdf
   Google Scholar